IBD-related carcinoma and lymphoma

Best Practice and Research: Clinical Gastroenterology

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Claessen, M M H ^a   Siersema, P D ^a   Vleggaar, F P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chemoprevention; Colorectal carcinoma; Dysplasia; Genomic instability; Inflammatory bowel disease; Surveillance

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; FOLIC ACID; K RAS PROTEIN; MERCAPTOPURINE; MULTIVITAMIN; PROTEIN P53; URSODEOXYCHOLIC ACID; WNT PROTEIN;

AGE DISTRIBUTION; ANEUPLOIDY; CANCER RISK; CARCINOGENESIS; CARCINOMA; CHEMOPROPHYLAXIS; CHROMOENDOSCOPY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DNA FINGERPRINTING; DNA METHYLATION; DYSPLASIA; EARLY DIAGNOSIS; FAMILY HISTORY; GASTROINTESTINAL CARCINOMA; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; REVIEW; SCLEROSING CHOLANGITIS; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 79958066830     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/S1521-6918(11)70007-5     Document Type: Article

References (88)

1. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010;138:746-74.
2. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-89.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
4. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62. (Pubitemid 32173312)
5. Lakatos L, Lakatos PL. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J 2006;82:332-7.
6. Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008;57:1246-51.
7. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33. (Pubitemid 20366527)
8. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988;29:206-17. (Pubitemid 18078890)
9. Mathy C, Schneider K, Chen YY, et al. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003;9:351-5. (Pubitemid 37461445)
10. Haskell H, Andrews Jr CW, Reddy SI, et al. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am J Surg Pathol 2005;29:1472-81.
11. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007;133:1099-105. (Pubitemid 47494461)
12. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9. (Pubitemid 38182302)
13. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995;22:1404-8.
14. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997;41:522-5.
15. Claessen MM, Vleggaar FP, Tytgat KM, et al. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009;50:158-64.
16. Claessen MM, Lutgens MW, van Buuren HR, et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009;15:1331-6.
17. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002;56:48-54. (Pubitemid 41115048)
18. Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 2001;120:1356-62. (Pubitemid 32322309)
19. Nuako KW, Ahlquist DA, Mahoney DW, et al. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998;115:1079-83. (Pubitemid 28485597)
20. Askling J, Dickman PW, Karlen P, et al. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 2001;357:262-6. (Pubitemid 32120857)
21. Greenstein AJ, Sachar DB, Smith H, et al. Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 1979;77(2):290-4. (Pubitemid 9206040)
22. Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010;138(5):1697-703.
23. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14(11):931-68.
24. Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001;194(2):152-7. (Pubitemid 32519963)
25. Choi PM, Nugent FW, Schoetz Jr DJ, et al. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993;105(2):418-24. (Pubitemid 23213526)
26. Karlen P, Lofberg R, Brostrom O, et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 1999;94(4):1047-52. (Pubitemid 29173626)
27. Lashner BA, Kane SV, Hanauer SB. Colon cancer surveillance in chronic ulcerative colitis: historical cohort study. Am J Gastroenterol 1990;85(9):1083-7. (Pubitemid 20348390)
28. Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009;101(10):1671-5.
29. Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992;103(5):1611-20.
30. Kiesslich R, Fritsch J, Holtmann M, et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003;124(4):880-8. (Pubitemid 36389789)
31. Marion JF, Waye JD, Present DH, et al. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol 2008;103(9):2342-9.
32. Rutter MD, Saunders BP, Schofield G, et al. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004;53(2):256-60.
33. Awais D, Siegel CA, Higgins PD. Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. Gut 2009;58(11):1498-503.
34. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343(8889):71-4.
35. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107(4):934-44. (Pubitemid 24294554)
36. Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003;125(5):1311-9. (Pubitemid 37409751)
37. van Schaik FD, ten Kate F, Offerhaus GJA, et al. Substantial increase of progression rate of flat low-grade dysplasia in inflammatory bowel disease after review by an expert pathologist panel. Gastroenterology 2010;138(5):s-45.
38. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287(1):G7-17.
39. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology 2010;138(6):2101-14.
40. Lindberg JO, Stenling RB, Rutegard JN. DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis. Br J Surg 1999;86(7):947-50. (Pubitemid 29333023)
41. Lofberg R, Brostrom O, Karlen P, et al. DNA aneuploidy in ulcerative colitis: reproducibility, topographic distribution, and relation to dysplasia. Gastroenterology 1992;102:1149-54.
42. Lofberg R, Lindquist K, Veress B, Tribukait B. Highly malignant carcinoma in chronic ulcerative colitis without preceding dysplasia or DNA aneuploidy. Report of a case. Dis Colon Rectum 1992;35(1):82-6.
43. Harpaz N, Peck AL, Yin J, et al. p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 1994;25(10):1069-74.
44. Bruwer M, Schmid KW, Senninger N, Schurmann G. Immunohistochemical expression of P53 and oncogenes in ulcerative colitis-associated colorectal carcinoma. World J Surg 2002;26(3):390-6. (Pubitemid 36920421)
45. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994;107(2):369-78. (Pubitemid 24233310)
46. Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 1992;103(5):1602-10.
47. Lashner BA, Shapiro BD, Husain A, Goldblum JR. Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis. Am J Gastroenterol 1999;94(2):456-62. (Pubitemid 29084669)
48. Holzmann K, Weis-Klemm M, Klump B, et al. Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis. Scand J Gastroenterol 2001;36(12):1320-6. (Pubitemid 33027813)
49. Claessen MM, Schipper ME, Oldenburg B, et al. WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance. Cell Oncol 2010;32(4):303-10.
50. Wong NA, Mayer NJ, MacKell S, et al. Immunohistochemical assessment of Ki67 and p53 expression assists the diagnosis and grading of ulcerative colitis-related dysplasia. Histopathology 2000;37(2):108-14. (Pubitemid 30608507)
51. Pinto D, Clevers H. Wnt control of stem cells and differentiation in the intestinal epithelium. Exp Cell Res 2005;306(2):357-63. (Pubitemid 40732761)
52. Tarmin L, Yin J, Harpaz N, et al. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 1995;55(10):2035-8.
53. Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 2002;94(5):1421-7. (Pubitemid 34212635)
54. van DH, Wink JC, Vissers KJ, et al. Wnt pathway-related gene expression during malignant progression in ulcerative colitis. Acta Histochem 2007;109(4):266-72. (Pubitemid 46962077)
55. Burmer GC, Levine DS, Kulander BG, et al. c-Ki-ras mutations in chronic ulcerative colitis and sporadic colon carcinoma. Gastroenterology 1990;99(2):416-20. (Pubitemid 20219098)
56. Haigis KM, Kendall KR, Wang Y, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 2008;40(5):600-8. (Pubitemid 351601205)
57. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP, et al. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 2003 Feb;162(2):665-72. (Pubitemid 36267873)
58. Deng G, Kakar S, Tanaka H, et al. Proximal and distal colorectal cancers show distinct gene-specific methylation profiles and clinical and molecular characteristics. Eur J Cancer 2008;44(9):1290-301.
59. Kuismanen SA, Holmberg MT, Salovaara R, et al. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000;156(5):1773-9. (Pubitemid 30646714)
60. Fleisher AS, Esteller M, Harpaz N, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 2000;60(17):4864-8.
61. Svrcek M, El-Bchiri J, Chalastanis A, et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol 2007;25(27):4231-8. (Pubitemid 47548563)
62. Willenbucher RF, Aust DE, Chang CG, et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 1999;154(6):1825-30. (Pubitemid 29262864)
63. Schulmann K, Mori Y, Croog V, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology 2005l;129(1):74-85.
64. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 2006;35(3):553-71. (Pubitemid 44307575)
65. Chang CL, Marra G, Chauhan DP, et al. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 2002;283(1):C148-54.
66. Fujii S, Fujimori T, Chiba T, Terano A. Efficacy of surveillance and molecular markers for detection of ulcerative colitis-associated colorectal neoplasia. J Gastroenterol 2003;38(12):1117-25. (Pubitemid 38128821)
67. Shen L, Ahuja N, Shen Y, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002;94(10):755-61. (Pubitemid 34567960)
68. Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology 2007 Apr;132(4):1254-60. (Pubitemid 46627571)
69. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 2001;61(9):3573-7. (Pubitemid 32694963)
70. Garrity-Park MM, Loftus Jr EV, Sandborn WJ, et al. Methylation status of genes in non-neoplastic mucosa from patients with ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2010;105(7):1610-9.
71. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100(6):1345-53. (Pubitemid 40904360)
72. Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98(12):2784-8.
73. Alberts DS, Martinez ME, Hess LM, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005;97(11):846-53. (Pubitemid 40909127)
74. Pardi DS, Loftus Jr EV, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124(4):889-93. (Pubitemid 36389790)
75. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134(2):89-95. (Pubitemid 32096335)
76. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85(11):875-84. (Pubitemid 23157127)
77. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112(1):29-32. (Pubitemid 27008982)
78. Velayos FS, Loftus Jr EV, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006;130(7):1941-9. (Pubitemid 43816957)
79. Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67(7):2015-9.
80. Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56(12):2914-21. (Pubitemid 16216306)
81. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54(5):617-22. (Pubitemid 40559243)
82. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121(5):1080-7. (Pubitemid 33022087)
83. Palli D, Trallori G, Bagnoli S, et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 2000;119(3):647-53.
84. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009;374(9701):1617-25.
85. von Roon AC, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 2007;50(6):839-55. (Pubitemid 46870441)
86. Palascak-Juif V, Bouvier AM, Cosnes J, et al. Small bowel adenocarcinoma in patients with Crohn's disease compared with small bowel adenocarcinoma de novo. Inflamm Bowel Dis 2005;11(9):828-32. (Pubitemid 41368271)
87. Feldstein RC, Sood S, Katz S. Small bowel adenocarcinoma in Crohn's disease. Inflamm Bowel Dis 2008;14(8):1154-7.
88. Solem CA, Harmsen WS, Zinsmeister AR, Loftus Jr EV. Small intestinal adenocarcinoma in Crohn's disease: a case-control study. Inflamm Bowel Dis 2004;10(1):32-5. (Pubitemid 38072443)